Affinity Technologies, Inc. (NASDAQ:BIAF) released its financial results for the year ended December 31, 2025, according to a statement issued Friday. The biotechnology company reported revenue of $6.

The MarketWatch News Department was not involved in the creation of this content. Laboratory business streamlined in 2025 to focus on profitable diagnostic testing services including the Company's ...

Record CyPath® Lung Revenue and Unit Sales. Revenue from our noninvasive diagnostic for lung cancer increased 87% over 2024 with the number of tests performed rising 99% year over year, reflecting ...

Detailed price information for Bioaffinity Technologies Inc (BIAF-Q) from The Globe and Mail including charting and trades.

SEVERE asthma was shown to involve a previously unrecognised wave of inflammatory lipid mediators, offering a potential new biomarker for assessing disease severity and treatment response. Researchers ...

Asthma may not be driven by the molecules scientists have blamed for decades. Researchers have identified “pseudo leukotrienes,” inflammation-triggering compounds formed by uncontrolled free-radical ...

Avoiding asthma triggers, like dust and smoke, can help prevent symptoms. Managing stress with methods like yoga and mindfulness can help control asthma. A diet rich in antioxidants and omega-3s can ...

Asthma is a chronic inflammatory condition marked by an imbalance in the immune response within the airways. According to Lancet, asthma affects around 339 million people globally. While conventional ...

Background Asthma is an umbrella diagnosis encompassing distinct pathophysiological mechanisms. While a global problem, our understanding of the interplay between respiratory microbiology and airway ...

Substantial progress has been made in the understanding and management of patients with asthma in recent years, yet this heterogeneous disease still poses an unacceptable health burden globally. The ...